<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04225923</url>
  </required_header>
  <id_info>
    <org_study_id>NPC-21-2</org_study_id>
    <nct_id>NCT04225923</nct_id>
  </id_info>
  <brief_title>A Study for Kidney Transplant Recipients at High-Risk of Cytomegalovirus Infection</brief_title>
  <official_title>A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of NPC-21 for Kidney Transplant Recipients at High-Risk of Cytomegalovirus Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nobelpharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nobelpharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to assess the efficacy and safety of NPC-21 when administered&#xD;
      prophylactically to cytomegalovirus (CMV) seronegative patients receiving a first kidney&#xD;
      transplant from a CMV seropositive donor.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 2, randomized, double-blind, placebo-controlled study of NPC-21 for kidney&#xD;
      transplant recipients at high risk of CMV infection in the United States and Japan.&#xD;
      Approximately 108 eligible patients will be randomized prior to first study drug&#xD;
      administration to receive low-dose NPC 21, high-dose NPC-21, or placebo. Randomization will&#xD;
      be stratified by region (United States or Japan)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2020</start_date>
  <completion_date type="Anticipated">February 2023</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of CMV disease or CMV viremia</measure>
    <time_frame>16 weeks</time_frame>
    <description>Percentage of patients with adjudicated CMV disease or CMV viremia through 16 weeks post-transplant</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of CMV disease or CMV viremia</measure>
    <time_frame>28 weeks</time_frame>
    <description>Percentage of patients with adjudicated CMV disease or CMV viremia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of CMV disease</measure>
    <time_frame>28 weeks</time_frame>
    <description>Percentage of patients with adjudicated CMV disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of CMV viremia</measure>
    <time_frame>28 weeks</time_frame>
    <description>Percentage of patients with adjudicated CMV viremia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to detectable CMV disease or CMV viremia</measure>
    <time_frame>28 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to detectable CMV disease</measure>
    <time_frame>28 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to detectable CMV viremia</measure>
    <time_frame>28 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of CMV DNA</measure>
    <time_frame>28 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and duration of anti-CMV therapy during the Rescue Phase</measure>
    <time_frame>28 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in EQ-5D-5L score from Baseline</measure>
    <time_frame>28 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">108</enrollment>
  <condition>Cytomegalovirus Disease</condition>
  <arm_group>
    <arm_group_label>NPC-21 Low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NPC-21 (Low dose) will be administered</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NPC-21 High dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NPC-21 (High dose) will be administered</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NPC-21 Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (normal saline) will be administered</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NPC-21 Low dose</intervention_name>
    <description>NPC-21 will be administered via an approximately 60-minute intravenous infusion</description>
    <arm_group_label>NPC-21 Low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NPC-21 High dose</intervention_name>
    <description>NPC-21 will be administered via an approximately 60-minute intravenous infusion</description>
    <arm_group_label>NPC-21 High dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NPC-21 Placebo</intervention_name>
    <description>Placebo will be administered via an approximately 60-minute intravenous infusion</description>
    <arm_group_label>NPC-21 Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female patients 18 to 75 years of age in the United States or 20 to 75 years&#xD;
             of age in Japan at the time of obtaining informed consent.&#xD;
&#xD;
          2. Patients must be CMV seronegative pre-transplant and scheduled to receive or have&#xD;
             received (within 7 days prior to first study drug administration) a first kidney&#xD;
             transplant from a CMV seropositive donor.&#xD;
&#xD;
          3. Patients must be willing and able to give written informed consent for participation&#xD;
             in the study.&#xD;
&#xD;
          4. Patients must be eligible to undergo kidney transplantation from a living or deceased&#xD;
             donor, as per institutional standards.&#xD;
&#xD;
          5. Patients must agree with contraception by using appropriate contraceptive measures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who have received a previous solid organ transplantation or hematopoietic&#xD;
             stem cell transplantation.&#xD;
&#xD;
          2. Patients who receive a multi-organ transplant.&#xD;
&#xD;
          3. Patients who have CMV disease or CMV viremia at Screening.&#xD;
&#xD;
          4. Patients who have a positive donor-specific antibody within 90 days prior to&#xD;
             Randomization confirmed via medical records.&#xD;
&#xD;
          5. Patients whose body weight is more than 120 kg at Screening.&#xD;
&#xD;
          6. Patients who have received the following anti-CMV therapy within 7 days prior to&#xD;
             Randomization and/or plan to receive the following anti-CMV therapy during the study:&#xD;
&#xD;
             ãƒ» Anti-CMV agents (eg, foscarnet, ganciclovir, valganciclovir, letermovir, high dose&#xD;
             acyclovir, high dose valacyclovir, high dose famciclovir, or cidofovir).&#xD;
&#xD;
             Note: The use of anti-CMV agents per local standard of care during the Rescue Phase of&#xD;
             the study is permitted.&#xD;
&#xD;
             Note: The use of anti-herpes simplex virus and anti-varicella zoster virus prophylaxis&#xD;
             for at-risk patients is recommended (as long as the doses are below the one specified&#xD;
             above).&#xD;
&#xD;
          7. Patients who have received the following therapy within 28 days prior to Randomization&#xD;
             and/or plan to receive the following anti-CMV therapy during the study:&#xD;
&#xD;
               -  CMV hyperimmune globulin (eg, CytoGam).&#xD;
&#xD;
               -  Intravenous immunoglobulin.&#xD;
&#xD;
               -  Plasmapheresis (receipt prior to first study drug administration is acceptable).&#xD;
&#xD;
          8. Patients with a history of a serious drug allergy to proteins, immunoglobulins,&#xD;
             transfusions, or vaccines or any excipient of the NPC-21 formulation.&#xD;
&#xD;
          9. Patients with severe hepatic insufficiency at Screening (eg, Child-Pugh Class C).&#xD;
&#xD;
         10. Patients with active and untreated hepatitis B virus or hepatitis C virus, as&#xD;
             documented as part of the pre-transplant screening.&#xD;
&#xD;
         11. Patients with known human immunodeficiency virus infection, based on medical records&#xD;
             serology.&#xD;
&#xD;
         12. Patients with any uncontrolled infection at Randomization or a history of serious and&#xD;
             uncontrolled infection within 6 months prior to Randomization.&#xD;
&#xD;
         13. Patients who are pregnant or lactating.&#xD;
&#xD;
         14. Patients with a history of malignancy within 5 years prior to Randomization other than&#xD;
             curatively treated in situ cervical carcinoma, cutaneous basal cell carcinoma, or&#xD;
             cutaneous squamous cell carcinoma.&#xD;
&#xD;
         15. Patients with a history of alcohol or drug abuse or dependence within 1 year prior to&#xD;
             Randomization that, in the opinion of the Investigator, would preclude study&#xD;
             participation.&#xD;
&#xD;
         16. Patients who have previously participated in this study or any other study involving&#xD;
             NPC-21.&#xD;
&#xD;
         17. Patients who have previously participated or are currently participating in any study&#xD;
             involving the administration of a CMV vaccine or another CMV investigational agent.&#xD;
&#xD;
         18. Patients who have participated in another interventional clinical study and received&#xD;
             another investigational product (ie, not approved by the Food and Drug Administration&#xD;
             in the United States or the Ministry of Health, Labour and Welfare in Japan) within 90&#xD;
             days before Randomization.&#xD;
&#xD;
         19. Patients who are unable or unwilling, in the opinion of the Investigator, to comply&#xD;
             with the protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>76 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Tatsuya Watanabe</last_name>
    <phone>+81-3-6670-3812</phone>
    <email>watanabe.tatsuya@nobelpharma.co.jp</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nobuyuki Takiguchi</last_name>
    <phone>:+81-3-6670-3815</phone>
    <email>takiguchi.nobuyuki@nobelpharma.co.jp</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mayo Clinic - Scottsdale</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>California Institute of Renal Research</name>
      <address>
        <city>La Mesa</city>
        <state>California</state>
        <zip>91942</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Augusta University Medical Center</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48084</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Christ Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati College of Medicine</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Renal Disease Research Institute</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research site_204</name>
      <address>
        <city>Nagakute</city>
        <state>Aichi</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research site_201</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research site_202</name>
      <address>
        <city>Toyoake</city>
        <state>Aichi</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research site_206</name>
      <address>
        <city>Kobe</city>
        <state>Hyogo</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research site_205</name>
      <address>
        <city>Nishinomiya</city>
        <state>Hyogo</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research site_212</name>
      <address>
        <city>Kumamoto-shi</city>
        <state>Kumamoto</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research site_215</name>
      <address>
        <city>Tomigusuku-shi</city>
        <state>Okinawa</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research site_211</name>
      <address>
        <city>Osaka-shi</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research site_214</name>
      <address>
        <city>Osaka-shi</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research site_208</name>
      <address>
        <city>Suita</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research site_203</name>
      <address>
        <city>Shimotsuke</city>
        <state>Tochigi</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research site_213</name>
      <address>
        <city>Hachioji-shi</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>January 9, 2020</study_first_submitted>
  <study_first_submitted_qc>January 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 13, 2020</study_first_posted>
  <last_update_submitted>October 21, 2021</last_update_submitted>
  <last_update_submitted_qc>October 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytomegalovirus Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

